Evidence map›Paper›PMID 40827908›Full record

SynthesisJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2025

Interventions for Bowen's disease: A systematic review and network meta-analysis of randomized controlled trials.

Yannick Foerster, Kristine Mayer, Marta Dechant, Julia Palaras, Tilo Biedermann, Oana-Diana Persa

Abstract readSystematic ReviewNetwork Meta-Analysis
In one paragraph

Synthesis in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Interventions for Bowen's disease: A systematic review and network meta-analysis of randomized controlled trials.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yannick FoersterDepartment of Dermatology, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.ORCID 0000-0001-5383-2263
Kristine MayerDepartment of Dermatology, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.ORCID 0000-0002-0044-5347
Marta DechantDepartment of Dermatology, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Julia PalarasDepartment of Dermatology, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Tilo BiedermannDepartment of Dermatology, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Oana-Diana PersaDepartment of Dermatology, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.ORCID 0000-0003-1469-4464

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bowen's disease (BD) is an intraepidermal malignancy that may progress to skin cancer, yet no study has compared interventions from randomized controlled trials (RCT). We synthesized RCT data to calculate lesion-specific initial clearance rates, long-term clearance rates, and cosmetic outcomes relative to placebo. We searched MEDLINE, EMBASE, CENTRAL and trial registers up to September 30, 2024, and included nine studies (672 patients, 844 lesions). Interventions compared to placebo and ranked via network meta-analysis included surgery, imiquimod, photodynamic therapy (PDT), laser ablation (LA), laser-assisted PDT (LA-PDT), cryotherapy and 5-fluoruracil (5-FU). Bias was assessed using the revised Cochrane risk-of-bias tool. The study was registered in PROSPERO prior to data extraction (CRD42024583966). All interventions showed higher lesion-specific clearance rates than placebo. Regarding initial clearance, LA-PDT ranked first, followed by surgery and LA. Surgery ranked first for long-term clearance, followed by LA-PDT and PDT. Cryotherapy and imiquimod ranked lowest for initial clearance and long-term clearance. PDT, LA-PDT, and 5-FU showed the best cosmetic outcome, while surgery had the worst. Limitations included moderate to high bias and study heterogeneity. Our findings support clinical decision-making for BD, identifying LA-PDT and PDT as effective options balancing efficacy and cosmetic results, and surgery as optimal for long-term clearance.

Indexed as

Bowen's DiseaseSkin NeoplasmsCryotherapyFluorouracilHumansImiquimodLaser TherapyPhotochemotherapyRandomized Controlled Trials as TopicTreatment OutcomeFluorouracilImiquimodBowenclearance rateSquamous cell carcinoma in situtherapy options

Identifiers

PMID40827908
PMCPMC12619046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.